Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 25

recruiting
3 968
countries
28
conditions
2 103

372 trials match your criteria

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab

Study on the Effectiveness and Safety of CYP-001 and Corticosteroids for Adults with High-Risk Acute Graft Versus Host Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Mesenchymoangioblast-Derived Mesenchymal Stem Cells

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1015550

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Dexamethasone
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.